## Erenumab Decreases Headache Related Sick Leave Days and Health Care Visits – A Retrospective Real-World Study in Working Patients With Migraine

**Henri Autio**<sup>1\*</sup>, Timo Purmonen<sup>1</sup>, Samu Kurki<sup>4</sup>, Emina Mocevic<sup>2</sup>, Minna A Korolainen<sup>1</sup>, Samuli Tuominen<sup>3</sup>, Mariann I Lassenius<sup>3</sup>, Markku Nissilä<sup>4</sup>


\*corresponding author

Henri Autio Novartis Finland Oy Metsänneidonkuja 10, 02130 Espoo, Finland e-mail: <u>henri.autio@novartis.com</u>

- 1. Novartis Finland Oy, Espoo, Finland
- 2. Novartis Healthcare A/S, Copenhagen, Denmark
- 3. Medaffcon Oy, Espoo, Finland
- 4. Terveystalo Biobank, Turku, Finland

**Supplementary material** 

Supplementary figure 1. Histogram of change in headache related sick leave days (A), all-cause sick leave days (B), and headache related visits (C), and all-cause visits (D) in erenumab treatment responders at 12 months pre (white) and post (grey) index. The number of days has been categorized to 0 [0]; 1 to 5 [1-5]; over 6 to 10 [6-10]; and over 10 [>10]. The Chi-squared test was used to test for changes in the number of patients in groups between pre and post index.



Number of healthcare visits, HA

Number of healthcare visits, all-cause